By Fineline Cube 
US-based Johnson & Johnson (NYSE: JNJ) announced the completion of its acquisition of fellow American company Intra-Cellular Therapies Inc. This move integrates Intra-Cellular into J&J’s Innovative Medicine division, marking a significant step in J&J’s strategic growth in the neuroscience sector. The acquisition, valued at USD 14.6 billion, is expected to contribute approximately USD 0.7 billion in incremental sales to J&J’s 2025 revenue, reflecting a 0.8% growth.
Acquisition Overview
The acquisition, first announced in January, has now been finalized, resulting in Intra-Cellular’s common stock ceasing trading on Nasdaq. This strategic move allows J&J to expand its neuroscience portfolio with Intra-Cellular’s innovative products.
Key Products
- Caplyta (lumateperone): A once-daily oral therapy approved in the US for treating depressive episodes associated with bipolar I or II disorder. It is also under regulatory review for use as an adjunctive treatment in major depressive disorder (MDD).
- ITI-1284: Currently in Phase II trials, this compound is being evaluated for generalized anxiety disorder (GAD) and Alzheimer’s disease-related psychosis and agitation.
Financial Impact
The acquisition is anticipated to enhance J&J’s financial performance in 2025, with significant contributions from Caplyta and the potential of ITI-1284. This acquisition underscores J&J’s commitment to advancing treatments in mental health and neurological disorders.-Fineline Info & Tech